Driving us mad: the association of *Toxoplasma gondii* with suicide attempts and traffic accidents – a systematic review and meta-analysis

Arjen L. Sutterland1, Anne Kuin1, Bouke Kuiper1, Tom van Gool2, Marion Leboyer3,4,5, Guillaume Fond3,4,5 and Lieuwe de Haan1

1Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Meibergdreef 5 1105 AZ, Amsterdam, The Netherlands; 2Department of Parasitology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands; 3Fondation Fondamental, Créteil 94000, France; 4Faculté de médecine, Université Paris-Est, Créteil 94000, France and 5INSERM, U955, Equipe 15, Créteil 94000, France

Abstract

Unnatural causes of death due to traffic accidents (TA) and suicide attempts (SA) constitute a major burden on global health, which remained stable in the last decade despite widespread efforts of prevention. Recently, latent infection with *Toxoplasma gondii* (*T. gondii*) has been suggested to be a biological risk factor for both TA and SA. Therefore, a systematic search concerning the relationship of *T. gondii* infection with TA and/or SA according to PRISMA guidelines in Medline, Pubmed and PsychInfo was conducted collecting papers up to 11 February 2019 (PROSPERO #CRD42018090206). The random-effect model was applied and sensitivity analyses were subsequently performed. Lastly, the population attributable fraction (PAF) was calculated. We found a significant association for antibodies against *T. gondii* with TA [odds ratio (OR) = 1.69; 95% confidence interval (CI) 1.20–2.38, *p* = 0.003] and SA (OR = 1.39; 95% CI 1.10–1.76, *p* = 0.006). Indication of publication bias was found for TA, but statistical adjustment for this bias did not change the OR. Heterogeneity concerning the relationship of *T. gondii* infection was 17% for TA and 10% for SA. This indicates that preventing *T. gondii* infection may play a role in the prevention of TA or SA, although uncertainty remains whether infection and outcome are truly causally related.

Introduction

Unnatural causes of death due to traffic accidents (TA) or suicide attempt (SA) constitute a major burden on global health. According to the World Health Organisation (WHO) about 1.4 million people die each year as a result of road injuries, rendering it one of the 10 leading causes of death globally for years (Naghavi et al., 2017). Between 20 and 50 million more people suffer from non-fatal road accidents, with many incurring a disability as a result of their injury. According to the WHO, TA are among the most important problems with regard to social, economic and human health issues (Naghavi et al., 2017). Likewise, suicide also has a huge impact on society, with 0.8 million people dying annually due to self-harm (Naghavi et al., 2017). For every fatal SA, 10–20 persons are estimated to attempt suicide, with approximately 10 million people attempting suicide worldwide annually (Turecki and Brent, 2016).

Both these causes of unnatural death are considered to be multifactorial, with psychological, social and biological factors involved (Turecki and Brent, 2016; Lutz et al., 2017). Resources are directed at addressing modifiable factors in policymaking (Perron et al., 2013; Goniweicz et al., 2016; Herbert et al., 2017) (i.e. making more difficult to jump of bridges, increasing road safety, preventing drug abuse) and healthcare (Goniweicz et al., 2016; Turecki and Brent, 2016; Gilissen et al., 2017) (improved immediate care for people involved in a car crash, lowering barriers for people with suicidal ideation to receive help) in order to diminish health burden. These interventions showed regional successes although without affecting global mortality rates in the last decade (Naghavi et al., 2017). Recently, a hitherto unsuspected, but potentially modifiable biological factor has received increasing attention with its association to both SA and TA: the latent infection with *Toxoplasma gondii* (*T. gondii*) (Flegr et al., 2009; Pedersen et al., 2012).
T. gondii is an intracellular and neurotropic parasite affecting most of the warm-blooded animals including humans. In humans, infection is acquired by ingestion of contaminated water or food that contains tissue cysts. It is estimated that approximately 30% of the global population is infected with the parasite, with large regional variances (Montoya and Liesenfeld, 2004). The parasite has a complex life cycle, whereby it needs to end up in the intestine of felines (cats) in order to complete its lifecycle (Montoya and Liesenfeld, 2004). Interestingly, non-feline mammals show cognitive and behavioural changes that increase their risk of being caught by felines (Berdoy et al., 2000; Webster, 2007), which are considered evolutionary adaptations of the parasite facilitating its survival. There is evidence that the parasite accomplishes this behavioural change by influencing neurotransmitters in the brain (Flegr, 2013; Parlog et al., 2015). Studies have shown that the parasite is able to increase dopamine release in infected neurons (Prandovszky et al., 2011) and potentially influences the kynurenine pathway, which could influence glutamate signalling (Notarangelo et al., 2014).

Since these findings emerged, research focussed increasingly on possible cognitive and behavioural changes by a latent T. gondii infection in humans. Indeed, neurocognitive changes have been reported in people with a latent T. gondii infection, whereby increased impulsiveness has been reported in people with T. gondii infection, although results so far are heterogeneous (Dickerson et al., 2014; Gale et al., 2015; Sugden et al., 2016; Peng et al., 2018). Nonetheless, meta-analyses did show overall a significant association of exposure to T. gondii with several psychiatric disorders, especially schizophrenia, suggesting that the infection could impact human behaviour as well (Sutterland et al., 2015).

The objective of the study was to determine if T. gondii infection is indeed associated with SA and/or TA by conducting a systematic review and meta-analysis.

Methods
We followed the systematic review guidelines provided by the PRISMA statement (Moher et al., 2009). We conducted a systematic search (see online Supplementary Appendix 1) throughout Medline, PsychInfo and EMBASE until 11 February 2019 (Prospero #CRD42018090206).

Inclusion criteria were: (i) original research papers with comparable quantitative data; (ii) any language; (iii) analysis of latent T. gondii infection by measuring IgG antibodies using one of the following diagnostic assays: Sabin–Feldman dye test, complement fixation, immune haemagglutination, immune fluorescence or enzyme-linked immunosorbent assay (ELISA); (iv) case–control or cohort studies with human subjects; (v) data on SA and/or TA. Exclusion criteria were: (i) studies without a control group, (ii) case reports or case series and (iii) studies with immunocompromised patients. Additional studies were sought in references to all reviews on this topic. Screening of search results by manuscript titles and abstracts were performed by three researchers (AS, BK, AK). Final screening by reading the whole manuscript was performed to validate inclusion (AS, AK). The corresponding authors were asked to provide additional data if not included in the original publications and for unpublished results.

All selected articles were screened on study quality independently by two researchers (AS, GF) following Cochrane criteria of quality on case–control or cohort studies (Higgins et al., 2011). If there was a difference in quality score, the difference was discussed. If consensus could not be reached, a third opinion was asked (LDH) for a final decision.

Some studies included only subjects which had committed SA as cases (e.g. cases presented at the emergency department due to a SA) and collected healthy controls as a control population in order to compare antibody levels against T. gondii. In contrast, other studies included subjects with certain psychiatric disorder (s) cross-sectionally and defined caseness as having a history of SA(s) and control population as subjects not having this history. In order to evaluate whether this difference in sampling method mattered, we stratified studies based on the type of control population used.

Meta-analysis of eligible studies
For all studies an odds ratio (OR) was calculated. ORs adjusted for confounders were used if available. The random-effects model was applied for all analyses. Heterogeneity was assessed by eyeballing and calculating $I^2$. Meta-analytical calculations were carried out with Comprehensive Meta-analysis Software 3.0 (Borenstein et al., 2013).

Effect of potential moderators on heterogeneity was assessed if possible (study quality, mean age, sex, seroprevalence of the control population, fatality, type of control population, diagnosis of cases and timing of outcome measurement: prospective or retrospective). Whether studies had a prospective design was determined based on the fulfillment of one of the following two criteria: (a) the study was designed as a longitudinal cohort study in which the assessment of seropositivity to T. gondii preceded the outcome (TA or SA) or (b) in a cross-sectional study the outcome (TA or SA) had occurred at or shortly before the measurement of IgG antibodies against T. gondii (since these antibodies are indicative of a latent infection and emerge months after primary infection). Considering the diagnosis of cases, specifically for SA, studies were grouped in studies that had included only cases with schizophrenia (schizophrenia only) compared with studies that had included other or any psychiatric disorder (various psychiatric disorders).

Where applicable meta-regression analysis (for continuous data) or subgroup analysis (for categorical data) were performed with the methods of moments and the mixed-effects model, respectively (Borenstein et al., 2009).

To assess by which proportion moderators influenced the variance of the true effect, regression analyses were performed investigating the moderator as a covariate. The amount of variance was expressed by $R^2$. Due to the number of included studies, moderator effects were analysed individually (Borenstein et al., 2009).

For seropositivity definition, cut-off scores used for the assays in the respective studies were used. If multiple assays were used in a study, we utilized the results of the assay that showed the smallest effect size.

Higher average antibody titres (compared with controls) have been called serointensity, whereby preferably numbers on high v. low, but still positive, antibody titres were used to see if this influenced the magnitude of the OR. If these were not available, average titres in groups were used and converted into an OR.

The potential for publication bias was assessed by examination of funnel plots and by the Egger’s test (which was considered significant if the one-sided $p$ value was <0.10). If applicable, Duval and Tweedie’s trim and fill method was used for a better estimation of the true OR.

Since the global incidence of TA and SA are both low (0.3–0.7% per year and 0.14% per year, respectively), OR becomes identical to the risk ratio (RR) (Zhang and Yu, 1998). As the
current meta-analysis provides an estimation of ORs and the global prevalence (Pglob) of a latent *T. gondii* is estimated to be 30% (Montoya and Liesenfeld, 2004), the population attributable fraction (PAF) can be calculated. The formula $\text{PAF} = \frac{\text{Pglob} \times (\text{RR} - 1)}{\text{Pglob} \times (\text{RR} - 1) + 1}$ was applied (Levin, 1953).

**Results**

The systematic search rendered in a total of 715 studies. After duplicate removal, 636 studies remained. After title and abstract screening for inclusion criteria, 51 studies were selected for full-text screening. Ten studies were added after reference screening of reviews. After full-text screening, 24 studies were finally selected for quantitative synthesis, with a total of 4229 cases and 12,234 controls in TA and 2259 cases and 9400 controls in SA (see Fig. 1 for flowchart and Table 1 for study characteristics).

**Traffic accidents**

In total, 11 studies comparing seropositivity to *T. gondii* with the risk of being involved in a TA were identified (Flegr et al., 2002; Yereli et al., 2006; Flegr et al., 2009; Kocazeybek et al., 2009; Galvan-Ramirez et al., 2013; Samojlowicz et al., 2013; Alvarado-Esquível et al., 2015; Shotar et al., 2016; Sugden et al., 2016; Stepanova et al., 2017; Burgdorf et al., 2019), showing an overall OR of 1.69 (95% CI 1.20–2.38, $p = 0.003$), see Fig. 2. The Egger’s test did indicate the presence of publication bias ($p = 0.06$), however the Duval and Tweedie’s trim and fill rendered the same OR using the random-effects model if missing studies were searched left from the mean. Also, the funnel plot using the random-effects model did not indicate publication bias (online Supplementary Appendix 2). Heterogeneity was considerable and significant ($I^2 = 86\%$, $p < 0.0001$, $\tau^2 = 0.247$).

To explore heterogeneity, moderators were assessed for their impact on the between-study variance. No effect of overall study quality on OR was found. Noteworthy, when quality of the definition of cases in TA was considered separately, the OR was significant in studies using a more concise description of TA (excluding alcohol use, making sure the driver was responsible for the accident), as opposed to those with broader inclusion criteria. Importantly, studies selectively assessing fatal TA as well as studies measuring antibodies against *T. gondii* occurring directly after or before the occurrence of TA (representing prospective study designs, as IgG antibodies against *T. gondii* represent a latent infection) both showed significant associations (Table 2a).

None of the moderators had a significant impact on the variance of the overall effect.

**Serointensity and TA**

In total, five studies reported serointensity (Flegr et al., 2002; Flegr et al., 2009; Kocazeybek et al., 2009; Galvan-Ramirez et al., 2013; Shotar et al., 2016). Overall, the odds for TA were increased in cases with high titres compared with low titres; OR 1.75 (95% CI 1.28–2.38; $p < 0.001$). Significant heterogeneity was present.
Table 1a. (a) Study characteristics of studies reporting *T. gondii* infection and traffic accidents

| Study (year) | Country     | Case population                                                                 | Control population                                                                 | Outcome measure                                                                 | Analysis method | Findings (n, % in cases and controls respectively)*a |
|--------------|-------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------|-----------------------------------------------------|
| Alvarado-Esquivel *et al.* (2015) | Mexico      | Interstate truck drivers with toxoplasmosis (n = 62) Age: unclear Gender: unclear | Interstate truck drivers without toxoplasmosis (n = 130) Total group (n = 192) Age(±s.e.): 43.4(10.2) years Gender: 97% male | History of traffic accidents                                                   | ELISA           | Seropositivity: 10/62 (16.1%) v. 13/130 (10%) Serointensity: not available |
| Burgdorf *et al.* (2019) | Denmark     | Blood donors who had a registered traffic accident (n = 2724) Age: 37.4 years (overall population) Gender: 55% male | Blood donors without registered traffic accident, matched on age, sex and parental history of psychiatric disorder with cases on time of blood sampling (n = 6294). Cases with a psychiatric disorder without traffic accident were included as controls | Registered as being involved in a traffic accident in Danish national patient register or Danish register of causes of death. Cases registered as pedestrian or passenger were excluded | Solid phase ELISA | Seropositivity: 723/2724 (27%) v. 1579/ 6294 (25%) Prospective subgroup; outcome after blood sampling: 206/751 (27%) v. 1309/ 5228 (25%) Serointensity: not available |
| Flegr *et al.* (2002) | Czech Republic | Outpatients at the surgery unit of the Kralovske Vinohrady Hospital, Prague (n = 146) Age: 15–70 years Gender: 58% male | Residents of central Prague, selected by quota sampling in a survey (n = 446) | History of traffic accidents. Only those who had negative alcohol laboratory test and actively influenced probability of their TA were included (judged by three independent persons) | CFT ELISA | Seropositivity: 58/146 (40%) v. 84/446 (19%) ORs stratified by age confirmed overall finding Serointensity: grouping according to low (8–16), moderate (32–64) and high antibody titres(≥64): OR 1.86 (95% CI 1.1–3.0), 4.78 (95% CI 2.4–9.6) and 16.03 (95% CI11.9–135.7) respectively Moderate or high v. low seropositive titres: 25/84 (30%) v. 18/84(21%) |
| Flegr *et al.* (2009) | Czech Republic | Male draftees who were involved in traffic accidents during follow-up of 1.5 years, while fulfilling compulsory military service (n = 111) Age: 20.4 Gender: 100% male | Male draftees who attended the Central Military Hospital in Prague for regular examinations for compulsory military service (n = 3890) Age(±s.e.): 20.1(±1.55) Gender: 100% male | Draftees who were involved in traffic accidents during follow-up of 1.5 years, while fulfilling compulsory military service (prospective cohort study) | CFT ELISA | Seropositivity: 28/111 (25.3%) v. 862/3779 (22.8%) When corrected for age, starting year of service and RhD: OR 2.56 (95% CI 1.1–5.7) Serointensity: increasing titre – interacting with RhD ($\chi^2 = 7.85, p = 0.02$) |

(Continued)
| Study (year)            | Country       | Case population                                              | Control population                                                         | Outcome measure                                                                 | Analysis method | Findings ($n$, % in cases and controls respectively)* |
|------------------------|---------------|--------------------------------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------|-------------------------------------------------------|
| Galvan-Ramirez et al.  | Mexico        | Drivers with traffic accidents ($n = 159$) Age(±s.a.): 37.1±11.8 years Gender: 76% male | Drivers without history of traffic accidents, randomly selected from same region ($n = 164$) Age(±s.a.): 39.7±11.8 years Gender: 76% male | Drivers sent for medical attention to hospital due to injuries caused by traffic accidents. People with positive alcohol tests were excluded | ELISA           | Seropositivity: 54/159 (34%) v. 59/164 (36%) Multivariate analysis corrected for age: OR 1.002 (95% CI 1.000–1.004) Detection of *T. gondii* DNA: 2/33 v. 1/38 Serointensity; average titres (±s.a.): 237.9 (±308.5) v. 122.9 (±112.7) |
| Kocazeybek et al.      | Turkey        | Group 1. Drivers presented at the emergency departments with traffic accidents ($n = 67$ non-fatal and $n = 25$ fatal) Age group 1: 33.8 (non-fatal) and 37.4 (fatal) years Age group 2: 37.8 years Gender group 1: 71.4% (non-fatal) and 96% (fatal) | Group 2. Subjects who presented at emergency departments in Istanbul before study started ($n = 151$) Age group 1: 33.8 (non-fatal) and 37.4 (fatal) years Age group 2: 37.8 years Gender group 2: 100% male Mean age overall: 36.7 Gender overall: 95.5% male | Group 1. Drivers acutely presented at the emergency departments who were involved in causing traffic accidents, had negative alcohol tests and had no neurological disorders (fatal and non-fatal) Group 2. Subjects with history of non-fatal traffic accidents who presented at emergency departments in Istanbul before study started. Negative alcohol tests, involved in traffic accidents and no neurological disorders | ELISA           | Seropositivity: 130/243 (53.5%) v. 56/200 (28%) Group 1: 49/92 (53.3%) Group 2: 81/151 (53.6%) Serointensity; average titres per group (±s.a.): Overall: 154.3±187 v. 102.5±213 Group 1: 205.8±252 Group 2: 122.2±182 Analysis with logistic regression analysis correcting for age: OR 1.72 (95% CI 1.4–2.1) |
| Samojlowicz et al.     | Poland        | People who died suddenly due to traffic accidents ($n = 42$) Age: 19–88, median = 40 Gender: 93% male | People who died suddenly due to disease, hypothermia, alcohol intoxication, injuries as passenger or being murdered ($n = 83$) Age: 20–89, median = 51 Gender: 92% male | Died due to traffic accidents, who were driving the vehicle. Analysis of alcohol available, not excluded | IF              | Seropositivity: 25/42 (60%) v. 41/83 (49%) Excluding alcohol use: 18/33 (54.5%) v. 16/40 (40%) Average titres not available Unadjusted for age and gender |
| Shotar et al.          | Jordan        | Drivers arrested and imprisoned for causing road TA ($n = 13$) Age(±s.a.): 32.9±7.5 Gender: 100% male | Healthy control population ($n = 200$) Age(±s.a.): unknown Gender: unknown | Drivers arrested and imprisoned for causing road accidents | ELISA           | Seropositivity: 2/13 (15.4%) v. 24/200 (12%) Mean IgG titres (±s.a.): 3.19 (±5.85) v. 1.98 (±1.14) |
ELISA Seropositivity: Healthy persons undergoing routine medical check-up (n = 39/152; 25.6%) OR adjusted for gender: 2.35 (95% CI 1.4–4.0). Gender: 53.9% male.

Driving conviction: Speeding, excess over 50; n = 89/601 (14.9%) Serointensity data not available. Serointensity: Not available. Age group-specific rates available.

ELISA, enzyme linked immunoassays; CFT, complement fixation test; IF, indirect fluorescence test. a Data of cases are presented first, control population second.

 Fifteen studies studying the association between SA and latent T. gondii infection and one unpublished study were identified (Arling et al., 2009; Yagmur et al., 2010; Okusaga et al., 2011; Pedersen et al., 2012; Zhang et al., 2012; Alvarado-Esquivel et al., 2013; Samojlowicz et al., 2013; Fond et al., 2015; Coryell et al., 2016; Sugden et al., 2016; Ansari-Lari et al., 2017; Bak et al., 2018; Burgdorf et al., 2019; Sutherland et al., 2019), with an overall OR of 1.39 (95% CI 1.10–1.76, p = 0006); see Fig. 3. One of the studies provided data on suicide deaths, violent SA as well as self-directed violence (Pedersen et al., 2012). Subjects with self-directed violence were excluded from the analysis. The Egger’s test did not indicate the presence of publication bias (p = 0.15) and Duval and Tweedie’s trim and fill analysis using the random-effects model rendered a similar and significant OR. There was evidence of heterogeneity (I² = 55%, p = 0003, R² = 0.103).

To explore heterogeneity, moderators were assessed for their impact on the between-study variance. Two moderators had a significant impact on the between-study variance: the proportion of patients with schizophrenia (schizophrenia only v. various psychiatric disorders) [OR_{schizophrenia} = 0.87 (95% CI 0.51–1.49), p = 0.62 v. OR_{various} = 1.8 (95% CI 1.44–2.24), p < 0.001] and whether the control population consisted of healthy controls or patients with psychiatric disorders [OR_{healthy controls} = 1.9 (95% CI 1.48–2.44), p < 0.001 v. OR_{psychiatric controls} = 1.06 (95% CI 0.70–1.61), p = 0.78] (Table 2b). In order to determine whether the effect of one moderator could drive the other, the effect of diagnosis within studies that used controls with psychiatric disorders was assessed post-hoc in studies with various psychiatric disorders as control subjects (n = 4) compared with only schizophrenia as control subjects (n = 5). A non-significant larger association was found [OR_{various} = 1.49 (95% CI 0.71–3.15), p = 0.29 v. OR_{schizophrenia} = 0.87 (95% CI 0.51–1.49), p = 0.62; Q-between 1.32, p = 0.25, R² = 0%]. It was not possible to investigate the reverse, since all studies investigating SA in subjects with schizophrenia did not use healthy controls as a comparison.

Importantly, studies that selectively assessed SA within a prospective design as well as fatal SA showed significant associations with T. gondii infection (Table 2b).

Even though the type of diagnosis of case population or type of control population explained a (trend)-significant amount of between-study variance, the estimated proportion of between-study variance was 0% for both moderators as expressed by R².

Serointensity and SA

Eight studies reported serointensity (Arling et al., 2009; Okusaga et al., 2011; Pedersen et al., 2012; Zhang et al., 2012; Alvarado-Esquivel et al., 2013; Fond et al., 2015; Ansari-Lari et al., 2017; Bak et al., 2018), rendering an overall OR of 1.22 (95% CI 0.96–1.55, p = 0.11). There was no indication of publication bias (Egger’s test p = 0.17). The heterogeneity of the observed effects between studies was high (I² = 62%, p = 0.004, τ = 0.252). When exploring possible reasons for the heterogeneity, there was a significant effect of studies focusing on subjects with schizophrenia (n = 5) v. various other psychiatric disorders (n = 5); OR 0.99 (95% CI 0.77–1.29) v. OR 1.66 (95% CI 1.29–2.12, p < 0.001), R² = 61%, p = 0.004.
Table 1b. (b) Study characteristics of studies reporting *T. gondii* infection and suicide attempts

| Study (year) | Country | Case population | Control population | Outcome measure | Analysis method | Findings (n, % in cases and controls respectively)* |
|--------------|---------|-----------------|--------------------|----------------|----------------|-----------------------------------------------|
| Alvarado-Esquivel et al. (2013) | Mexico | Outpatients with various psychiatric disorders (*n* = 156) Age (±S.D.): 34.0 (±10.3) years Gender: 24% male | Outpatients with various psychiatric disorders (*n* = 127) Age (±S.D.): 38.3 (±11.6) years Gender: 40% male | History of suicide attempt(s) | ELISA | Seropositivity: 7/156 (5%) vs. 10/127 (8%) High antibody titres (>150 IU/ml): 7/7 (100%) vs. 5/10 (50%) |
| Ansari-Lari et al. (2017) | Iran | Patients with schizophrenia (*n* = 42) Age (±S.D.): 43.5 (±8.1) years Gender: 76.2% male | Patients with schizophrenia (*n* = 57) Age (±S.D.): 38.0 (±11.1) years Gender: 70.2% male | History of suicide attempt(s) | ELISA | Seropositivity: 8/42 (19%) vs. 21/57 (37%) Mean IgG values (±S.D.), adjusted for age, gender and race: 7.7 (±11.7) vs. 12.5 (±13.7) |
| Arling et al. (2009) | USA | Patients with mood disorders (major depressive disorder or bipolar I or II disorder), (*n* = 99) Age (±S.D.): 40.3 (±9.8) years Gender: 39% male | Patients with mood disorders (major depressive disorder or bipolar I or II disorder), (*n* = 119) Age (±S.D.): 43.4 (±10.9) years Gender: 36% male | History of suicide attempt(s) measured by Columbia suicide history form identifying suicide attempts with (some) intent to die, interrupted attempt and ambiguous attempt | Solid phase ELISA | Seropositivity: OR 1.62 (95% CI 0.72–3.65) Geometric Mean IgG values (±S.D.), adjusted for age, gender and race: 0.51 (±0.46) vs. 0.37 (±0.50) |
| Bak et al. (2018) | Korea | In- and outpatients seeking treatment for suicide attempts with depressive symptoms (*n* = 155) Age: 43.7 years Gender: 39% male | Healthy controls with no history of psychiatric disorders (*n* = 135) Age: 42.6 years Gender: 48.9% male | History of suicide attempt(s) (non-suicidal automutilation ruled out) | CLIA | Seropositivity: 21/155 (14%) vs. 8/135 (6%) High antibody titres (>150 IU/ml): 7/21 (33%) vs. 2/8 (25%) |
| Burgdorf et al. (2019) | Denmark | Blood donors with registered suicide attempt or suicide (*n* = 655) Age: 37.4 years (overall) Gender: 42.4% male | Blood donors without registered suicide attempt or suicide, matched on age, sex and parental history of psychiatric disorder with cases on time of blood sampling (*n* = 6503) Cases with a psychiatric disorder without suicide (attempt) were included as controls | Registered suicide attempt in Danish national patient register or suicide in Danish register of causes of death | Solid phase ELISA | Seropositivity: 193/655 (29%) vs. 1633/6503 (25%) Prospective subgroup; outcome after blood sampling: 3/23 (13%) vs. 1319/5259 (25%) Serointensity: not available |
| Coryell et al. (2016) | USA | Adolescents starting treatment with SSRI, in- and outpatients (*n* = 17) Age (±S.D.): 17.5 (±1.7) years Gender: 29% male | Adolescents starting treatment with SSRI, in- and outpatients (*n* = 91) Age (±S.D.): 19.0 (±1.6) years Gender: 24% male | History of suicide attempt(s), defined as any self-harm intended to cause death | ELISA | 2/17 (12%) vs. 2/91 (2%) seropositive Mean IgG values (±S.D.): Adjusted for age and gender |
| Fond et al. (2015) | France | Inpatients with bipolar disorder type I and II (*n* = 54) Age (±S.D.): 48.1 (±12.0) years Gender: 46% male | Inpatients with bipolar disorder type I and II (*n* = 97) Age (±S.D.): 42.3 (±13.7) years Gender: 52% male | History of suicide attempt(s) and suicide intentionality and lethality according to the Columbia-suicide severity rating scale | Solid phase ELISA | Seropositivity: 45/54 (83%) vs. 69/97 (71%) Serointensity (mean titre ±S.D.): 3.30 (±1.47) vs. 2.84 (±1.69) |
| Study                        | Country       | Inpatients with schizophrenia or schizoaffective disorder | Inpatients with schizophrenia or schizoaffective disorder (n = 61) | History of suicide attempt(s) and suicide intentionality and lethality according to the Columbia-suicide severity rating scale | Solid phase ELISA | Seropositive: | Serointensity (mean titre ±S.D.): |
|-----------------------------|---------------|------------------------------------------------------------|-------------------------------------------------|---------------------------------------------------------------------------------|------------------|----------------|-----------------------------------|
| Fond et al. (2015)          | France        | (n = 43)                                                    | Age (±S.D.): 36.2 (±11.4) years Gender: 70% male                                      |                                                                                 |                  | 30/43 (70%) | v. 44/61 (72%)                      |
|                            |               |                                                             |                                                 |                                                                                 |                  | 2.68 (±1.69) | v. 2.53 (±1.81)                      |
| Sutterland et al. (2019)    | The Netherlands| (n = 61)                                                   | Age (±S.D.): 35.4 (±11.5) years Gender: 75% male                                      |                                                                                 |                  | 2/33 (6%) | v. 49/285 (17%)                      |
|                            |               |                                                             |                                                 |                                                                                 |                  |                |                                    |
| Okusaga et al. (2011)       | Germany       | (n = 372)                                                  | Age (±S.D.): 40.8 (±11.8) years Gender: 51% male                                      |                                                                                 |                  | 26/41 (63%) | v. 41/83 (49%)                      |
|                            |               |                                                             |                                                 |                                                                                 |                  |                |                                    |
| Pedersen et al. (2012)      | Denmark       | (n = 488)                                                  | Age: not applicable, but all analyses adjusted for age Gender: 0% male              |                                                                                 |                  |                |                                    |
| Samojlowicz et al. (2013)   | Poland        | (n = 41)                                                   | Age: 18–81, median = 40 years Gender: 88% male                                       |                                                                                 |                  |                |                                    |

(Continued)
| Study (year)       | Country     | Case population                                                                 | Control population                                                                 | Outcome measure                                                                 | Analysis method | Findings (n, % in cases and controls respectively)\(^a\) |
|-------------------|-------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------|-------------------------------------------------------------|
| Sugden et al. (2016) | New Zealand | Dunedin birth cohort who were \(T.\) \(gondii\) positive and tested at age 38 \((n = 236)\)
Age: 38
Gender: 58% male | Dunedin birth cohort who were \(T.\) \(gondii\) negative and tested at age 38 \((n = 601)\)
Age: 38
Gender: 47% male | History of suicide attempt(s) with non-suicidal self-injury ruled out, occurring since last assessment at age 32 | ELISA | Suicide attempt since age 32: 8/236 (3.4%) v. 8/601 (1.3%) |
| Yagmur et al. (2010) | Turkey     | Patients with various psychiatric disorders presenting at the emergency department with a suicide attempt \((n = 200)\)
Age\((\text{s.d.})\): 24.3(±7.6) years
Gender: 21% male | Healthy controls, including health caseworkers and relatives/visitors of patients \((n = 200)\)
Age\((\text{s.d.})\): 24.3(±8.0) years
Gender: 23% male | Presentation with suicide attempt at emergency department | ELISA | Seropositivity: 82/200 (41%) v. 56/200 (28%) Matched on age, gender, SES, urbanicity and dietary habits |
| Zhang et al. (2012) | Sweden     | Inpatients with various psychiatric disorders admitted \((n = 54)\)
Age\((\text{s.d.})\): 38.4(±14.4) years
Gender: 43% male | Healthy controls recruited in same municipality \((n = 30)\)
Age\((\text{s.d.})\): 39.8(±14.2) years
Gender: 37% male | Admitted due to a suicide attempt, defined as actual or seemingly life-threatening behaviour with intent to jeopardize his/her life or to give such appearance, not resulting in death | ELISA | Seropositivity: 22/54 (41%) v. 6/30 (20%) Age-adjusted log-transformed mean IgG titres\((\text{s.d.})\): 3.0(±0.1) v. 2.6(±0.2) |

ELISA, enzyme linked immunoassays; CFT, complement fixation test; IF, indirect fluorescence test; CLIA, chemiluminescent immunoassay.

\(^a\)Data of cases are presented first, control population second.
T. gondii showed that if (95% CI 3–17%) (95% CI 6–29%) and due to SA with 10% (95% CI 3–19%).

Population attributable fraction
Assuming an average infection rate of T. gondii of 30% in humans globally, the calculated PAF, \[ \frac{0.3 \times (OR - 1)}{0.3 \times (OR - 1) + 1} \], showed that if T. gondii infection would theoretically be completely prevented, the casualties due to TA would decrease with approximately 17% (95% CI 6–29%) and due to SA with 10% (95% CI 3–19%).

Discussion
Overall we found significant associations between a T. gondii infection and both SA and TA. Importantly, the associations did not seem to be influenced by publication bias. If the associations would be explained by the causal hypothesis, i.e. that the T. gondii infection influences the risk of committing a SA or suffering a TA, this would imply that a latent T. gondii infection would lead to much more morbidity and mortality than hitherto assumed. Taking into account the calculated PAFs, T. gondii infection would emerge as a major public health concern, comparable with global meningitis mortality, with estimated 318,000 annual deaths potentially due to the behavioural effects of this infection (Naghavi et al., 2017). Therefore, it is paramount to evaluate whether the results of the current meta-analysis and the available literature to date indeed provide enough support for the plausibility of a causal relationship and whether alternative explanations for these associations could be given.

When assessing whether a factor (here a T. gondii infection) could be causal to a certain condition, Koch’s postulates of causality can be used as a theoretical framework (Antonelli and Cutler, 2016). The postulates that need to be addressed in order for a factor to be considered causal to a certain condition are: consistency of the relationship, a temporal relationship (the factor preceding the emergence of the condition), a gradient in the relationship (more exposure to the factor leads to a higher risk of getting the condition), experimental proof of the relationship and a plausible biological mechanism.

The consistency of the relationship is addressed with the current meta-analysis. Overall the associations were significant, although the amount of studies was modest and heterogeneity high. In TA the Egger’s test indicated the presence of publication bias. Nevertheless, statistical adjustment for possible bias by the Duval and Tweedie’s trim and fill analysis did not change the overall finding. This is probably due to the different underlying mathematical method these tests use. The Egger’s test relies on the fixed-effects model to see whether the sample size influences overall effect, whereas the Duval and Tweedie’s trim and fill analysis can be applied to both the fixed- and random-effects model (Borenstein et al., 2009). This implies that the Egger’s test relies more heavily on sample size, whereby the large Danish cohort study that found a small but significant association of T. gondii with TA has a very large weight (>70%) relative to the other studies (all 5% or less) (Burgdorf et al., 2019). When funnel plots were examined using both the fixed- and random-effects model, it became clear that with the random-effects model (which gives relatively less weight to large studies than the fixed-effects model) there does not seem to be a publication bias (see online Supplementary Appendix 2). Additionally, even when the fixed-effects model was used for statistical correction, the OR remained significantly increased albeit smaller (data available upon request). In our view, despite the significant Egger’s test, the data still indicate a relationship between T. gondii and TA, although the magnitude is less certain. When exploring heterogeneity in TA, assessable moderators explained a negligible and non-significant amount of the observed variance. In favour of the consistency of the relationship with TA was that the OR seemed to be stronger when studies were grouped which had carefully selected subjects with a higher chance to have influenced their own risk of becoming involved in TA (not intoxicated, having caused the accident as a driver).

In SA there was no indication of publication bias, but (trend-) significant effects on heterogeneity were found among studies that included subjects with schizophrenia only and those that used healthy subjects as control population. A secondary analysis seemed to indicate that selection of schizophrenia cases is particularly important, whereby the association of T. gondii infection with SA was absent in cases with schizophrenia. This might be due to the fact that T. gondii infection is a risk factor for schizophrenia in itself (Sutterland et al., 2015) or that the infection has little effect on suicidality in schizophrenia specifically, where other factors may overshadow such a relationship. For example, Toxoplasma infection has been associated with dopamine

![Fig. 2. Forest plot toxoplasmosis and traffic, accidents using the random-effects model.](https://doi.org/10.1017/S0033291719000813) Published online by Cambridge University Press
Table 2a. (a) Moderator assessment in association traffic accidents with toxoplasmosis

| Moderator assessed                                      | Number of studies available | Analysis method                           | Coefficient | Findings                                                                                     |
|---------------------------------------------------------|----------------------------|-------------------------------------------|-------------|--------------------------------------------------------------------------------------------|
| Seroprevalence of control population                    | 11                         | Regression analysis with methods of moments | -0.016 (95% CI -0.047 to -0.015) \(p = 0.32\) | \(R^2 = 10\%\) |
| Seroprevalence of control population (dichotomized in low v. high seroprevalence) | 11 (5 and 6)               | Mixed-effects analysis                     | OR low(<24%) = 1.99 (95% CI 1.08–3.68) \(p = 0.03\) OR high(>24%) = 1.49 (95% CI 1.02–2.18) \(p = 0.04\) Q between = 0.61, \(p = 0.43\) | \(R^2 = 15\%\) |
| Average age of controls                                 | 7                          | Regression analysis with methods of moments | 0.001 (95% CI -0.040 to -0.043) \(p = 0.96\) | \(R^2 = 0\%\) |
| Gender (male or female)                                 | 10 (5 and 5)               | Mixed-effects analysis                     | OR male = 2.85 (95% CI 1.77–4.58) \(p = 0.007\) OR female = 2.14 (95% CI 1.24–3.71) \(< 0.001\) Q between = 0.59, \(p = 0.42\) | \(R^2 = 0\%\) |
| Quality of studies (continuous)                         | 11                         | Regression analysis with methods of moments | -0.020 (95% CI -0.115 to -0.076) \(p = 0.69\) | \(R^2 = 10\%\) |
| Quality of studies (dichotomized)                       | 11 (5 + 6)                 | Mixed-effects analysis                     | OR (<4) = 1.87 (95% CI 0.92–3.76) \(p = 0.08\) OR (>4) = 1.56 (95% CI 1.07–2.68) \(p = 0.02\) Q between = 0.19, \(p = 0.66\) | \(R^2 = 9\%\) |
| Quality of traffic accident definition\(^a\)             | 11 (4 and 7)               | Mixed-effects analysis                     | OR (poor) = 1.36 (95% CI 0.91–2.02) \(p = 0.13\) OR (good) = 1.92 (95% CI 1.22–3.02) \(p = 0.005\) Q between = 1.29, \(p = 0.26\) | \(R^2 = 0\%\) |
| Fatality of traffic accidents (fatal or non-fatal)\(^b\)  | 12 (one dataset split on fatality) (2 and 10) | Mixed-effects analysis                     | OR fatal 2.08 (95% CI 1.38–3.15) \(p = 0.001\) OR non-fatal 1.70 (95% CI 1.19–2.44) \(p = 0.004\) Q between = 0.52, \(p = 0.47\) | \(R^2 = 0\%\) |
| Timing of measurement traffic accidents (prospective or retrospective) | 11 (6 and 5)               | Mixed-effects analysis                     | OR prospective 1.60 (95% CI 1.04–2.48) \(p = 0.03\) OR retrospective 1.89 (95% CI 1.18–2.80) \(p = 0.01\) Q between = 0.25, \(p = 0.62\) | \(R^2 = 12\%\) |

\(p\)-values < 0.05 are highlighted in bold.
\(^a\)Good definition of being a case suffering a traffic accident in a study is assuring the case is the driver, which has (most probably) caused the traffic accident, excluding people who had drunk alcohol and/or used drugs.
\(^b\)Studies reporting both fatal and non-fatal were excluded when separate data were not available.
\(^b\)For this moderator prospective data only were analysed for the study of Burgdorf et al.
Table 2b. (b) Moderator assessment in association suicide attempts with toxoplasmosis

| Moderator assessed                              | Datasets available | Method                                | Findings                                                                 |
|------------------------------------------------|--------------------|---------------------------------------|--------------------------------------------------------------------------|
| Seroprevalence of control population           | 17                 | Regression analysis with methods of   | Coefficient 0.0001 (95% CI −0.014 to 0.014) \( p = 0.99 \) \( R^2 = 0\% \) |
| Average age of controls                        | 11                 | Regression analysis with methods of   | Coefficient −0.008 (95% CI −0.07 to 0.05) \( p = 0.80 \) \( R^2 = 0\% \) |
| Gender (male or female)                        | 6 [3 and 3]        | Mixed-effects analysis                | OR male = 0.97 (95% CI 0.53–1.76) \( p = 0.91 \) OR female = 1.73 (95% CI 0.37–7.97) \( p = 0.48 \) Q between = 0.49, \( p = 0.49 \) |
| Quality of studies (continuous)                | 17                 | Regression analysis with methods of   | Coefficient 0.048 (95% CI −0.14 to 0.23) \( p = 0.61 \) \( R^2 = 0\% \) |
| Quality of studies (dichotomized)              | 17 [8 and 9]       | Mixed-effects analysis                | OR (<5) 1.36 (95% CI 0.89–2.07) \( p = 0.16 \) OR (> = 5) 1.40 (95% CI 1.04–1.88) \( p = 0.03 \) \( R^2 = 0\% \) |
| Fatality of suicide attempts (fatal or non-fatal)* | 17 [2 and 15]      | Mixed-effects analysis                | OR fatal 1.91 (95% CI 1.05–3.45) \( p = 0.03 \) OR non-fatal 1.34 (95% CI 1.04–1.73) \( p = 0.04 \) Q between = 1.12, \( p = 0.29 \) \( R^2 = 0\% \) |
| Diagnosis (schizophrenia or any psychiatric disorder) | 17 [5 and 12]      | Mixed-effects analysis                | OR schizophrenia 0.87 (95% CI 0.51–1.49) \( p = 0.62 \) OR any 1.64 (95% CI 1.27–2.11) \( p < 0.001 \) \( R^2 = 0\% \) |
| Type of control population (psychiatric disorders or healthy controls) | 17 [9 and 8]       | Mixed-effects analysis                | OR psychiatric disorders 1.06 (95% CI 0.70–1.61) \( p = 0.78 \) OR healthy controls 1.67 (95% CI 1.27–2.20) \( p = 0.001 \) Q between = 3.16, \( p = 0.08 \) \( R^2 = 0\% \) |
| Timing of measurement suicide attempts in regard to seropositivity to *T. gondii* (prospective or retrospective) | 17 [11 and 6]b     | Mixed-effects analysis                | OR retrospective 1.24 (0.83–1.83) \( p = 0.29 \) OR prospective 1.68 (1.25–2.26) \( p = 0.001 \) \( R^2 = 3\% \) |

\( p \)-values < 0.05 are highlighted in bold.

*a*Studies reporting both fatal and non-fatal suicide attempts were excluded when separate data were not available. To measure the OR for fatal suicide attempts in the study of Pedersen et al., the adjusted relative risk had to be used.

*b*For this moderator prospective data only were analysed for the study of Burgdorf et al.
modulation in brain neurons (Prandovszky et al., 2011), while dopamine disturbances are generally recognized abnormalities described in the brain of most subjects with schizophrenia whether or not they are infected with T. gondii (Howes et al., 2017). Nonetheless, the association of T. gondii infection with SA being partly explained by using healthy subjects as controls remains a concern, suggesting the higher prevalence of antibodies against T. gondii in several psychiatric disorders might drive the association. On one hand this possible confounding seems less likely as the large cohort study of Pedersen et al. was able to control for psychiatric disorders in the population and still showed a significant association between T. gondii infection and suicidal behaviour (Pedersen et al., 2012), but on the other hand the study of Burgdorf et al. found a small but non-significant effect, whereby they used a different method to control for psychiatric disorders in the population (Burgdorf et al., 2019). Future studies should keep trying to disentangle these confounding factors and assess other potential factors influencing heterogeneity.

One of those candidates is Rhesus factor positivity, which has been suggested as relevant (Flegr et al., 2009; Flegr et al., 2013). For example, cognitive dysfunction was only found in subjects with a latent T. gondii infection which were Rhesus negative. Why the Rhesus factor could protect humans against deleterial effects of T. gondii is unclear. Another candidate to explore is the strain hypothesis, which states that strains of T. gondii in several psychiatric disorders might drive the association. On one hand this possible confounding seems less likely as the large cohort study of Pedersen et al. was able to control for psychiatric disorders in the population and still showed a significant association between T. gondii infection and suicidal behaviour (Pedersen et al., 2012), but on the other hand the study of Burgdorf et al. found a small but non-significant effect, whereby they used a different method to control for psychiatric disorders in the population (Burgdorf et al., 2019). Future studies should keep trying to disentangle these confounding factors and assess other potential factors influencing heterogeneity.

The experimental proof for a relationship is challenging with the studied outcomes. Animal models have been examined, which could be applicable to these outcomes. Several behavioural changes after infection with T. gondii in mice and rats have been documented, including increased reaction time, slower neural processing speed, decreased attention span and increased risk-taking behaviour (Webster, 2007; Daniels et al., 2015; Tan et al., 2015). These factors can increase the risk of both TA and SA. However, the methodology underlying these findings has been questioned (Worth et al., 2014). Human studies have indicated cognitive abnormalities concurring with T. gondii infection, increasing the risk of suffering from TA (Guenther et al., 2012; Pearce et al., 2013; Pearce et al., 2014). However, these findings were not always replicated (Gale et al., 2015; Sugden et al., 2016).

Finally, a plausible biological mechanism should be available to explain how a latent T. gondii infection could lead to an increased risk of causing TA and SA. Several biological mechanisms have been postulated. First of all, as tryptophan is essential for T. gondii replication, increased tryptophan breakdown by activating the kynurenine pathway is a major line of defence for the host against T. gondii infection, leading to increased kynurenine (KYNN) and quinolinic acid (QUIN) levels (Miller et al., 2009).
Increased KYN as well as QUIN levels, including in CSF and post-mortem, have been associated with suicidal behaviour (Sublette et al., 2011; Steiner et al., 2012; Erhardt et al., 2013). Okusaga et al. found that the risk of SA was increased in cases with both seropositivity to *T. gondii* and high KYN levels (Okusaga et al., 2016). QUIN is an N-methyl-D-aspartate (NMDA) receptor agonist and considered to be neurotoxic, whereby recent evidence indicates that ketamine, an NMDA receptor antagonist can acutely reduce suicidality (DiazGranados et al., 2010). Secondly, it has been demonstrated that a *T. gondii* infection can increase dopamine levels both in vitro and in mice (Skalova et al., 2006; Prandovszky et al., 2011). The genome of *T. gondii* is able to express the enzyme tyrosine hydroxylase in infected cells, which is the rate-limiting enzyme in dopamine synthesis (Prandovszky et al., 2011). Hyperdopaminergic states, together with NMDA agonism, can lead to increased arousal, neurotoxicity and impulsivity (Barake et al., 2014).

Although the suggested biological mechanisms may be plausible, studies confirming the role of one of these mechanisms in humans are challenging and remain scarce (Okusaga et al., 2016).

Alternative explanations for an association between *T. gondii* infection and both SA and TA should be explored as well. As it is known that felines are the definite host of the parasite, households with cats are more prone to get infected by *T. gondii*. While we are unaware of studies showing that families who prefer cats as pets are also more prone to psychiatric illness, SA or TA, this reverse causality cannot be ruled out. Conversely, evidence that households with cats have an increased risk of developing schizophrenia has been published (Torrey et al., 2015), although these findings have been challenged (Solmi et al., 2017).

When elaborating further on factors that could give rise to a so-called spurious association (i.e. toxoplasmosis and TA or SA are not directly related to each other but both rise or fall due to another factor), it should be noted that households with low incomes are known to be at a higher risk of being involved in a TA or committing a SA (Qin et al., 2003; Ghaffar et al., 2004; Hawton and van Heeringen, 2009). There is an indication that this could also be applicable to the risk of contracting a latent *T. gondii* infection (Mareze et al., 2019). Studies included in our meta-analysis did not adjust for socio-economic status, which would be important to examine in future studies.

Furthermore, it is possible that the biological susceptibility of humans to contract a latent *T. gondii* infection, for example, through differences in the immune defence system or reactivity of the kynurenine pathway, also influences the risk of TA and SA. In SA, many studies have shown changes in cytokine profiles in cases compared with controls (Gananca et al., 2016), but in TA this has not been examined as far as we are aware. More studies with a prospective design focusing on biological susceptibility are needed to shed further light on this matter.

### Strengths and limitations

One of the strengths of the meta-analysis is the extensive sensitivity analysis addressing heterogeneity, after retrieval of additional data from several authors. This showed variation in the association of SA with *T. gondii* infection, due to several factors, which can guide the field in further research into this topic. It was also able to demonstrate that the severity of *T. gondii* infection further increased the association with SA and TA and that the infection precedes these adverse outcomes. One of the limitations, however, is that the amount of studies was still relatively modest, leaving some uncertainty about the robustness of the finding and limiting options for sensitivity analyses with multiple moderators at once. Another limitation was that it was not possible to use individual patient data.

### Conclusion

Overall, the findings of this meta-analysis in conjunction with the available literature provide substantial support for the hypothesis that a latent *T. gondii* infection may play an important role in the risk of TA and SA. However, although there is some support for the interpretation that the association is causal, causality is not proven. Nevertheless, the additional impact that toxoplasmosis potentially has on health [besides the well-known consequences in immunocompromised patients and *de novo* infection during pregnancies and the possible mental health consequences (Montoya and Liesenfeld, 2004)] validates the question what the gain could be for devoting more public health resources into this issue. Further research concerning the prevention of primary infections on a larger scale should be considered. It is presumed that transmission occurs most often through ingestion of intact oocysts containing the parasite, which can be contracted by eating raw or undercooked meat, changing cat litter, by not washing hands after gardening, eating unwashed vegetables or fruit or by drinking contaminated water (Montoya and Liesenfeld, 2004). It would be good to increase the knowledge about the most common route of transmission in humans and try to prevent this. Alternatively, resources could be directed into developing a vaccine for humans or cats. Secondly, little is known how to diminish or prevent deleterious consequences by an acquired latent infection. Targeting specific high-risk populations, such as traffic offenders or people who have committed a SA could be an option to investigate these questions. Finally, possible candidates that could be responsible for the heterogeneous findings (rhesus factor positivity, differences in strain virulence, type of case and control population) should be explored further.

### Supplementary material

The supplementary material for this article can be found at https://doi.org/10.1017/S0033291719000813

### Author ORCIDs

Arjen L. Sutterland, 0000-0001-9206-2492

### Acknowledgements

We would like to thank Joost Daams, clinical librarian, for help on developing the search strategy. We would also like to thank the authors who provided additional data on their studies for this meta-analysis: Cosme Alvarado-Esquivel, Karen Sugden, Bouke Kuiper, Marianne Pedersen and Guillaume Fond.

### Financial support

Not applicable.

### References

Alvarado-Esquivel C, Sanchez-Anguiano LF, Arnaud-Gil CA, Lopez-Longoria JC, Molina-Espinoza LF, Estrada-Martinez S, Liesenfeld O, Hernandez-Tinoco J, Sifuentes-Alvarez A and Salas-Martinez C (2013) *Toxoplasma gondii* infection and suicide attempts: a case-control study in psychiatric outpatients. *Journal of Nervous and Mental Disease* 201, 948–952.

Alvarado-Esquivel C, Pacheco-Vega SJ, Hernandez-Tinoco J, Salcedo-Jaquez M, Sanchez-Anguiano LF, Berumen-Segovia LO, Rabago-Sanchez E and Liesenfeld O (2015) *Toxoplasma gondii* infection in interstate truck drivers: a case-control seroprevalence study. *Parasites and Vectors* 8, 77.

Ansari-Lari M, Farashbandi H and Mohammadi F (2017) Association of *Toxoplasma gondii* infection with schizophrenia and its relationship with...
suicide attempts in these patients. *Tropical Medicine and International Health* 22, 1322–1327.

Antonelli G and Cutler S (2016) Evolution of the Koch postulates: towards a 21st-century understanding of microbial infection. *Clinical Microbiology and Infection* 22, 583–584.

Arling TA, Yolken RH, Lapidus M, Langenberg P, Dickerson FB, Zimmerman SA, Balis T, Cabassa JA, Scardins DA, Tonelli LH and Postolache TT (2009) *Toxoplasma gondii* antibody titers and history of suicide attempts in patients with recurrent mood disorders. *Journal of Nervous and Mental Disease* 197, 905–908.

Bak J, Shim S-H, Kwon Y-J, Lee H-Y, Kim JS, Yoon H and Lee YJ (2018) The association between suicide attempts and *Toxoplasma gondii* infection. *Clinical Psychopharmacology and Neuroscience* 16, 95–102.

Barake M, Evins AE, Stoeckel L, Pachas GN, Nachtigall LB, Miller KK, Biller BM, Tritos NA and Klibanski A (2014) Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. *Pituitary* 17, 150–156.

Berdoy M, Webster JP and Macdonald DW (2000) Fatal attraction in rats infected with *Toxoplasma gondii*. *Proceedings Biological Sciences* 267, 1591–1594.

Borenstein M, Hedges LV, Higgins JPT and Rothstein RR (2009) *Introduction to Meta-Analysis*. West Sussex, United Kingdom: John Wiley & Sons, Ltd.

Borenstein M, Hedges L, Higgins J and Rothstein H (2013) *Comprehensive Meta-Analysis Version 3*. Englewood, NJ: Biostat.

Burgdorf KS, Trabjerg BB, Pedersen MG, Nissen J, Banasik K, Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Flegr J, Klose J, Novotna M, Berenreitterova M and Havlicek J (2013) How and why Toxoplasma makes us crazy. *Neuropsychopharmacology* 38, 743–752.

Calarge C, Flegr J, Preiss M and Klose J (2013) Toxoplasmosis-associated difference in intelligence and personality in men depends on their Rhesus blood group but not ABO blood group. *PLoS ONE* 8, e61272.

Fond G, Boyer L, Gaman A, Lauamnn H, Attiba D, Richard J-R, Delavest M, Houenou J, Le Corvoisier P, Charron D, Krishnamoorthy R, Oliveira J, Tamouza R, Yolken R, Dickerson F, Leboyer M and Hamdani N (2015) Treatment with anti-toxoplasomal activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: a cross-sectional study. *Journal of Psychiatric Research* 63, 58–64.

Gale SD, Brown BL, Erickson LD, Berrett A and Hedges DW (2015) Association between latent toxoplasmosis and cognition in adults: a cross-sectional study. *Parasitology* 142, 557–565.

Galvan-Ramirez M, Sanchez-Orozco LV, Rodriguez LR, Rodriguez S, Roig-Melo E, Troyo Sanroman R, Chiquete E and Armendariz-Borunda J (2013) Seroposidemiology of Toxoplasma gondii infection in divers involved in road traffic accidents in the metropolitan area of Guadalajara, Jalisco, Mexico. *Parasites and Vectors* 6, 294.

Ganlanca L, Oquendo MA, Tyrka AR, Cisneros-Trujillo S, Mann J and Sublette ME (2016) The role of cytokines in the pathophysiology of suicidal behavior. *Psychoneuroendocrinology* 63, 296–310.

Gargate MJ, Ferreira I, Vilares A, Martins S, Cardoso C, Silva S, Nunes B and Gomes JP (2016) *Toxoplasma gondii* seroprevalence in the Portuguese population: comparison of three cross-sectional studies spanning three decades. *British Medical Journal Open* 6, e011648.

Ghaffar A, Hyder AA, Govender V and Bishai D (2004) Road crashes: a modern plague on South Asia’s poor. *Journal of the College of Physicians and Surgeons – Pakistan* 14, 739–741.

Gillisen R, De Beurs D, Molkenstorm J, Merelle S, Donker G, Terpstra S, Derijck C and Franx G (2017) Improving Suicide Prevention in Dutch Regions by Creating Local Suicide Prevention Action Networks (SUPRANET): a study protocol. *International Journal of Environmental Research and Public Health* 14, E349.

Goniewicz K, Goniewicz M, Pawlowski W and Fiedor P (2016) Road accident rates: strategies and programmes for improving road traffic safety. *European Journal of Trauma and Emergency Surgery* 42, 433–438.

Groer MW, Yolken RH, Xiao JC, Beckstead JW, Fuchs D, Mohapatra SS, Seyfang A and Postolache TT (2011) Prenatal depression and anxiety in *Toxoplasma gondii*-positive women. *American Journal of Obstetrics and Gynecology* 204, 433, e1–7.

Guenter W, Bielinski M, Deptula A, Zalus-Wiecek P, Piskunowicz M, Szowd K, Bucinski A, Gospodarek E and Borkowska A (2012) Does Toxoplasma gondii infection affect cognitive function? A case control study. *Folia Parasitologica (Praga)* 59, 93–98.

Hawton K and van Heeringen K (2009) Suicide. *Lancet* 373, 1372–1381.

Herbert A, Gilbert R, Cottrell D and Li L (2017) Causes of death up to 10 years after admissions to hospitals for self-inflicted, drug-related or alcohol-related, or violent injury during adolescence: a retrospective, nationwide, cohort study. *Lancet* 390, 577–587.

Higgins JPT, Altman D and Sterne J (2011). Assessing risk of bias in included studies. In *Cochrane Handbook for Systematic Reviews of Interventions*. The Cochrane Collaboration. Version 5.1.0 [updated 2011]. Chapter 8. Available at http://www handbook.cochrane.org.

Howes OD, McCutcheon R, Owen MJ and Murray RM (2017) The role of genes, stress, and dopamine in the development of schizophrenia. *Biological Psychiatry* 81, 9–20.

Huikari S, Miettunen J and Korhonen M (2019) Economic crises and suicides between 1970 and 2011: time trend study in 21 developed countries. *Journal of Epidemiology and Community Health* 73, 311–316.

Jones JL, Kruszon-Moran D, Rivera HN, Price C and Wilkins P (2014) *Toxoplasma gondii* seroprevalence in the United States 2009–2010 and comparison with the past two decades. *The American Journal of Tropical Medicine and Hygiene* 90, 1135–1139.

Kocayezbek B, Oner YA, Turksoy R, Babur C, Cakan H, Sahip N, Unal A, Ozaslan A, Kilic S, Saribas S, Aslan M, Taylan A, Koc S, Dirican A, Uner HB, Oz V, Ertekin C, Kucukbasmaci O and Torun MM (2009) Higher prevalence of toxoplasmosis in victims of traffic accidents suggest increased risk of traffic accident in Toxoplasma-infected inhabitants of Istanbul and its suburbs. *Forensic Science International* 187, 103–108.

Lester D (2010) Predicting European suicide rates with physiological indices. *Psychological Reports* 107, 713–714.
Levin ML. (1953) The occurrence of lung cancer in man. Acta – Unio Internationale Contra Cancrum 9, 531–541.

Lutz PE, Mechawar N and Turecki G (2017) Neuropathology of suicide: recent findings and future directions. Molecular Psychiatry 22, 1395–1412.

Mareze M, Benitez ADN, Brandao APD, Pinto-Ferreira F, Miura AC, Martins FDC, Caldart ET, Biondo AW, Freire RL, Mitsuoka-Bregano R and Navarro IT (2019) Socioeconomic vulnerability associated to Toxoplasma gondii exposure in southern Brazil. PLoS ONE 14, e0212375.

Miller CM, Boultier NR, Ikin RJ and Smith NC (2009) The immunobiology of the innate response to Toxoplasma gondii. International Journal for Parasitology 39, 23–39.

Moher D, Liberati A, Tetzlaff J and Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 62, 1006–1012.

Montoya JG and Liesenfeld O (2004) Toxoplasmosis. Lancet 363, 1965–1976.

Naghashi M, Abajobir AA and Abbafati C and GBD 2016 Causes of Death Collaborators (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1151–1210.

Notarangelo F, Wilson E, Horning K, Thomas M, Harris T, Fung Q, Hunter C and Schwartz R (2014) Evaluation of kynurenic pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. Schizophrenia Research 152, 261–267.

Okusaga O, Langenberg P, Sleemi A, Vaswani D, Giegling I, Hartmann AM, Konte B, Friedell M, Groer MW, Wolken RH, Rujescu D and Postolache TT (2011) Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia. Schizophrenia Research 133, 150–155.

Okusaga O, Duncan E, Langenberg P, Brundin L, Fuchs D, Groer MW, Giegling I, Hartmann AM, Konte B, Friedell M, Brenner LA, Lowry CA, Rujescu D and Postolache TT (2016) Combined Toxoplasma gondii seropositivity and high blood kynurenine linked with nonfatal suicidal self-directed violence in patients with schizophrenia. Journal of Psychiatric Research 72, 74–81.

Parlog A, Schluter D and Dunay IR (2015) Toxoplasma gondii induces neuronal alterations. Parasite Immunology 37, 159–170.

Pearce BD, Hubbard S, Rivera HN, Wilkins PP, Fisch MC, Hopkins MH, Hasenkamp W, Gross R, Blwise N, Jones JL and Duncan E (2013) Toxoplasma gondii exposure affects neural processing speed as measured by acoustic startle latency in schizophrenia and controls. Schizophrenia Research 150, 258–261.

Pearce BD, Kruszon-Moran D and Jones JL (2014) The association of Toxoplasma gondii infection with neurocognitive deficits in a population-based analysis. Social Psychiatry and Psychiatric Epidemiology 49, 1001–1010.

Pedersen MG, Mortensen PB, Norgaard-Pedersen B and Postolache TT (2012) Toxoplasma gondii infection and self-directed violence in mothers. Archives of General Psychiatry 69, 1123–1130.

Peng X, Brenner LA, Mathai AJ, Cook TB, Fuchs D, Postolache N, Groer MW, Pandey JP, Mohyuddin F, Giegling I, Wadhawan A, Hartmann AM, Konte B, Brundin L, Friedell M, Lapidus M, Grunebaum MF, Sublette ME, Galfalvy HC, Fuchs D, Postolache TT, Torrey E, Simmons W and Yolken RH (2016) suicide and suicidal behaviour. PLoS ONE 11, e0148435.

Rutter A, Fant L, Kirk S, Mortensen PB, Qin P, Agerbo E and Mortensen PB (2003) Suicide risk in relation to socioeconomic, demographic, psychiatric, and familial factors: a national register-based study of all suicides in Denmark, 1981–1997. The American Journal of Psychiatry 160, 765–772.

Samoljowicz D, Borowska-Solonyko A and Golab E (2013) Prevalence of Toxoplasma gondii parasite infection among people who died due to sudden death in the capital city of Warsaw and its vicinity. Przegląd Epidemiologiczny 67, 115–118.

Shotar A, Alzyoud SA and Alkhathib AJ (2016) Latent toxoplasmosis and the involvement in road traffic accidents among a sample of Jordanian drivers. Research Journal of Medical Sciences 10, 194–198.

Skalova A, Kodym P, Frynta D and Flegr J (2006) The role of dopamine in Toxoplasma-induced behavioural alterations in mice: an ethological and ethopharmacological study. Parasitology 133, 525–535.

Solmi F, Hayes J, Lewis G and Kirkbride J (2017) Curiosity killed the cat: no evidence of an association between cat ownership and psychotic symptoms at ages 13 and 18 years in a UK general population cohort. Psychological Medicine 47, 1659–1667.

Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG and Miyint AM (2012) Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. The World Journal of Biological Psychiatry 13, 482–492.

Stepanova EV, Kondrashin AV, Sergeev VP, Morozova LF, Turbanina NA, Maksimova MS, Brazhnikov AI, Shevchenko SB and Morozov EN (2017) Significance of chronic toxoplasmosis in epidemiology of road traffic accidents in Russian Federation. PLoS ONE 12, e0184930.

Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Osquoeno MA, Mann JJ and Postolache TT (2011) Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain, Behavior, and Immunity 25, 1272–1278.

Sugden K, Moffitt TE, Pinto L, Poulton R, Williams BS and Caspi A (2016) Is Toxoplasma gondii infection related to brain and behavior impairments in humans? Evidence from a population-representative birth cohort. PLoS ONE 11, e0148435.

Sutherland AL, Keuper B, Ribbens JJ, Mourin DA, Van Gool T and de Haan I (2019) Latent Toxoplasma gondii infection is associated with psychosis but not suicidal ideation in psychosis. In Preparation.

Tan D, Soh LJ, Lim LW, Daniel TC, Zhang X and Vyas A (2015) Infection of male rats with Toxoplasma gondii results in enhanced delay aversion and neural changes in the nucleus accumbens core. Proceedings Biological Sciences 282, 20150042.

Torrey E, Simmons W and Wolken RH (2015) Is childhood cat ownership a risk factor for schizophrenia later in life? Schizophrenia Research 165, 1–2.

Turecki G and Brent DA (2016) Suicide and suicidal behaviour. Lancet 387, 1227–1239.

Webster JP (2007) The effect of Toxoplasma gondii on animal behavior: playing cat and mouse. Schizophrenia Bulletin 33, 752–756.

Worth AR, Andrew Thompson RC and Lynbery AJ (2014) Reevaluating the evidence for Toxoplasma gondii-induced behavioural changes in rodents. Advances in Parasitology 85, 109–142.

Xiao J, Buka SL, Cannon TD, Suzuki Y, Viscido RP, Torrey EF and Wolken RH (2009) Serological pattern consistent with infection with type I Toxoplasma gondii in mothers and risk of psychosis among adult offspring. Microbes and Infection 11, 1011–1018.

Yagmur F, Yazar S, Temel HO and Cavusoglu M (2010) May Toxoplasma gondii increase suicide attempt-pretiminary results in Turkish subjects? Forensic Science International 199, 15–17.

Yereli K, Balcigliu IC and Ozgibilin A (2006) Is Toxoplasma gondii a potential risk for traffic accidents in Turkey? Forensic Science International 163, 34–37.

Zhang J and Yu KF (1998) What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280, 1690–1691.

Zhang Y, Traskman-Bendz L, Janelidze S, Langenberg P, Saleh A, Constantine N, Okusaga O, Bay-Richter C, Brundin L and Postolache TT (2012) Toxoplasma gondii immunoglobulin G antibodies and nonfatal suicidal self-directed violence. The Journal of Clinical Psychiatry 73, 1069–1076.